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OBJECTIVE—Metformin can decrease adiposity and ameliorate
obesity-related comorbid conditions, including abnormalities in
glucose homeostasis in adolescents, but there are few data
evaluating the efﬁcacy of metformin among younger children.
Our objective was to determine whether metformin treatment
causes weight loss and improves obesity-related comorbidities in
obese children, who are insulin-resistant.
RESEARCH DESIGN AND METHODS—This study was a ran-
domized double-blind placebo-controlled trial consisting of 100
severely obese (mean BMI 34.6 6 6.6 kg/m
2) insulin-resistant
children aged 6–12 years, randomized to 1,000 mg metformin
(n = 53) or placebo (n = 47) twice daily for 6 months, followed
by open-label metformin treatment for 6 months. All children and
their parents participated in a monthly dietitian-administered
weight-reduction program.
RESULTS—Eighty-ﬁve percent completed the 6-month random-
ized phase. Children prescribed metformin had signiﬁcantly
greater decreases in BMI (difference 21.09 kg/m
2,C I21.87 to
20.31, P = 0.006), body weight (difference 23.38 kg, CI 25.2 to 2
1.57, P , 0.001), BMI Z score (difference between metformin and
placebo groups 20.07, CI 20.12 to 20.01, P = 0.02), and fat mass
(difference 21.40 kg, CI 22.74 to 20.06, P = 0.04). Fasting
plasma glucose (P = 0.007) and homeostasis model assessment
(HOMA) insulin resistance index (P = 0.006) also improved more
in metformin-treated children than in placebo-treated children.
Gastrointestinal symptoms were signiﬁcantly more prevalent in
metformin-treated children, which limited maximal tolerated dos-
age in 17%. During the 6-month open-label phase, children treated
previously with placebo decreased their BMI Z score; those trea-
ted continuously with metformin did not signiﬁcantly change BMI
Z score further.
CONCLUSIONS—Metformin had modest but favorable effects
on body weight, body composition, and glucose homeostasis in
obese insulin-resistant children participating in a low-intensity
weight-reduction program. Diabetes 60:477–485, 2011
T
he prevalence of pediatric obesity has increased
substantially since the 1970s; 19.6% of children
6–11 years of age are now considered obese
(BMI $95th percentile standard for age and sex)
(1). Excess body fat in children is associated with insulin
resistance and dysglycemia (2) and predicts development
of the metabolic syndrome in adulthood (3). Insulin re-
sistance is of particular concern because it is indepen-
dently associated with metabolic abnormalities during
childhood (2,4) and development of type 2 diabetes (5–7).
Intensive behavioral treatments, which may reduce ad-
iposity among children with moderately increased body
weight (8), have limited efﬁcacy among individuals most
severely affected (9–12), leading to interest in developing
other effective approaches. There have been few con-
trolled pediatric trials of antiobesity agents. There are
currently no medications that are approved by the U.S.
Food and Drug Administration (FDA) to treat obesity in
children ,12 years of age.
Metformin recently received attention for its potential to
assist in pediatric weight control efforts (13). Metformin is
FDA-approved for treatment of type 2 diabetes in children
age $10 years; it suppresses hepatic glucose production
(14) and, at high concentrations, improves peripheral in-
sulin sensitivity (15). Metformin induces weight stabiliza-
tion or small weight losses in diabetic (16–19) and
nondiabetic (20–23) adults. Case series involving obese
children (24–26) and relatively small randomized trials in
obese adolescents (27–33), including one 48-week multi-
center trial (33), also suggest that metformin may induce
small BMI/weight reductions, averaging ;1.4 kg/m
2 (3 kg)
over 6 months (34,35) and 1.1 kg/m
2 over 1 year (33). Small
trials also suggest that metformin has a positive impact on
insulin resistance and hyperandrogenism in patients with
polycystic ovary syndrome (36,37) or precocious pubarche
(38,39). However, no randomized controlled trials have
evaluated the effect of metformin on body weight and
body composition in severely obese children age 6–12
years. Studies involving this age-group are important be-
cause some research suggests that obesity may be more
tractable when treated during childhood (40).
We studied the effects of metformin in obese children
aged 6–12 years who were believed to be at particular risk
because they manifested a signiﬁcant degree of insulin
resistance. We hypothesized that, in the context of a
weight-reduction program, metformin would decrease
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ORIGINAL ARTICLEchildren’s body weight, BMI, and fat mass; improve in-
sulin sensitivity; and ameliorate aspects of the metabolic
syndrome.
RESEARCH DESIGN AND METHODS
Study sample. Obese children, aged 6–12 years, recruited through newspaper
advertisements and letters to physicians, were eligible if they had BMI $95th
percentile according to the Centers for Disease Control and Prevention 2000
growth charts for the United States; were prepubertal or early pubertal (de-
ﬁned as breast Tanner stage I–III for girls; testes ,8 mL for boys); and had
fasting hyperinsulinemia, deﬁned as fasting insulin $15 mU/mL, the 99th
percentile for fasting insulin among 224 nonobese 6- to 12-year-old children
studied as outpatients at the National Institutes of Health (NIH) with the same
insulin assay (unpublished data). This cut point is also consistent with some
prior adult data (41). Children were excluded if they had impaired fasting
glucose, were diabetic, or reported a diagnosed renal, cardiac, endocrine,
pulmonary, or hepatic disease that might alter body weight. Subjects were
excluded for baseline creatinine .1 mg/dL and for alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) that exceeded 1.5 times the upper
limit of the laboratory normal range. The study was approved by the In-
stitutional Review Boards of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD), NIH, and the Phoenix Area
Indian Health Service. Written assent and consent were obtained from chil-
dren and their parents. The study was overseen by a Data and Safety Moni-
toring Board convened by NICHD.
Design overview. We conducted a single-center trial from September 2000 to
August 2008. After an outpatient screening visit, participants were admitted as
inpatients to the NIH Clinical Research Center (CRC) for assessment and then
entered a 6-month randomizedplacebo-controlleddouble-blind treatmentperiod
and were then readmitted for reassessment. Participants who completed the
randomized phase were offered an additional 6 months of open-label metformin.
Randomization and interventions. We randomly assigned participants in
a 1:1 randomization ratio to receive metformin hydrochloride or placebo, twice
daily with meals. Investigators assigned consecutive code numbers to partic-
ipants from prespeciﬁed lists stratiﬁed by race/ethnicity, sex, and degree of
pubertal development. The CRC Pharmaceutical Development Section used
permuted blocks with stratiﬁcation to generate allocations that translated code
numbers into study group assignments by using a pseudo-random number
program and prepared identically appearing placebo and metformin (U.S.P.
Grade; SST Corporation, Clifton, NJ) capsules (250 mg/capsule). Pharmacy
personnel not involved with the conduct of the study dispensed study capsules
in containers that differed only by participant code number. No participant,
investigator, or other medical or nursing staff interacting with participants was
aware of study group assignments during the trial.
Oncebaselineassessmentswerecompleted,subject’s studymedicationdose
was progressively increased according to a prespeciﬁed algorithm over a
3-week period, starting with 500 mg twice daily and increasing to a maximum
dose of 1,000 mg twice daily. The typical adult maximum dose was selected as
the goal because the weight of the severely obese participants to be enrolled
(Table 1) was anticipated to be similar to that of adults. We decreased the dose
by 250 mg/dose for 1 week when participants reported difﬁculty tolerating
study medication and then attempted to increase it. Study medication dose was
progressively lowered by 250 mg/day if a prescribed dosage could not be tol-
erated after a 7-day trial. Once a tolerated dose was found, attempts were made
to increase the dosage prescribed. Study medication was discontinued if 250
mg/day was not tolerated. A daily chewable multivitamin (Flintstones Com-
plete) containing 6 mg cyanocobalamin was also prescribed. After conclusion
of the randomized phase, participants were prescribed increasing doses of
commercially available metformin in two divided doses with a maximum dose
of 2,000 mg/day plus a daily multivitamin for an additional 6 months.
During both study phases, each participant and a parent/guardian met
monthly with a dietitian who administered a weight-reduction lifestyle modiﬁ-
cation program that promoteda reduced-energydiet, increasedphysical activity,
and decreased inactivity. Participants were trained to complete a baseline 7-day
food diary that was reviewed by a registered dietitian. These data were used to
offer individualized prescriptions for a “trafﬁcl i g h t ” style (42) 500 kcal/day–
deﬁcit diet that reduced fat and energy intake. The exercise prescription con-
sisted of encouraging 30 min of aerobic exercise every day and inclusion of
lifestyle exercise whenever possible and was monitored by pedometer readings
recorded by parents. Adherence was gauged through self-monitoring of medi-
cation taken, food eaten, activity performed, amount of inactive time, and pe-
dometer readings recorded in a progress book that was reviewed monthly.
Initial assessment. Subjects who met inclusion criteria were admitted as
inpatients to the CRC for the following measurements: weight in a hospital
gown using a calibrated digital scale (Life Measurement Instruments, Concord,
CA); height in triplicate using astadiometer (Holtain, Crymych, U.K.) calibrated
before each measurement; abdominal and hip circumferences (assessed in
triplicate) and triceps skinfold thickness (Lange calipers; Cambridge Scientiﬁc
Industries, Cambridge, MD) by trained research dietitians (C.G.S. and N.G.S.);
blood pressure using an automated sphygmomanometer (Dinamap-Plus;
Critikon, Tampa, FL) measured in the seated position after at least 5 min rest;
a hand roentgenogram for determination of skeletal age; whole-body fat mass
by dual-energy X-ray absorptiometry (DEXA) (4500A; Hologic, Bedford, MA;
software version 11.2) and by air displacement plethysmography; and intra-
abdominal and subcutaneous abdominal adipose tissue by magnetic resonance
imaging at L2–L3 and L4–L5 (T1-weighted spin-echo images, 0.5 T, relaxation
time 400 ms, time of excitation 10 ms, number of repetitions of excitations 10).
A 2-h hyperglycemic (200 mg/dL) clamp was also performed at baseline and
follow-up admissions to estimate insulin sensitivity and ﬁrst-phase insulin
secretion as previously described (43). First-phase insulin was calculated as
the mean of measurements obtained during the ﬁrst 15 min. Whole-body
glucose uptake (metabolic rate: M) was deﬁned as the infusion rate of exog-
enous glucose administered, corrected for urinary glucose losses and the
glucose space correction. As a measure of insulin sensitivity (SIclamp) the ratio
of metabolic rate to steady-state insulin (M/I) was calculated.
At baseline and follow-up, samples obtained in the fasted state were col-
lected for measurement of ALT, AST, total and HDL cholesterol, direct LDL
cholesterol, and triglycerides (Synchron LX20; Beckman Coulter, Fullerton,
CA). Plasma for glucose was collected in tubes containing powdered sodium
ﬂuoride and measured by the NIH CRC clinical laboratory using a Roche
Diagnostics (Indianapolis, IN) analyzer. C-reactive protein was measured by a
high-sensitivity assay(IMMAGEImmunochemistry Systems;Beckman Coulter)
with sensitivity of 0.020 mg/dL. Vitamin B12 and insulin were measured by
chemiluminescent immunoassays using Siemens Healthcare Diagnostics (Los
Angeles, CA) Immulite instruments. Fasting samples were used to estimate
insulin resistance by the homeostasis model assessment–insulin resistance
(HOMA-IR) index = insulin (mU/mL) 3 [glucose (mmol/L)/22.5]. Diagnosis of
pediatric metabolic syndrome was made when three or more components
were present from among the following: waist circumference, blood pressure,
and triglycerides $90th percentile for age and sex; HDL cholesterol #10th
percentile for age and sex; and fasting glucose $100 mg/dL (44).
Subjects and parents were also interviewed by a clinical pharmacist who
used a structured questionnaire containing a comprehensive list of symptoms
designed to identify potential adverse drug reactions (45).
Outcomes and follow-up measures. The prespeciﬁed primary study end
point was change in BMI SD score (BMI Z), as determined at the end of the
6-month randomized treatment phase. Secondary outcomes were changes in
BMI, body weight, and fat mass at the conclusion of the randomized phase.
Tertiary outcomes included changes in skinfold thickness, body circum-
ferences, visceral adipose tissue, insulin resistance, and laboratory compo-
nents of the metabolic syndrome.
Participants were seen monthly and exchanged their unused study medi-
cation for a new supply at each visit. We used the tally of returned capsules to
assess adherence. Measurements of BMI, bloodpressure, liverfunction, plasma
lactate, and serum vitamin B12 were obtained at each visit, along with an in-
terim history obtained using a structured list of queries. After 6 months of
treatment, subjects were re-evaluated and then offered open-label metformin
for a second 6-month treatment period with continued monthly visits.
Statistical analysis. Power was based on prior data we collected examining
BMI change over 6 months in obese 6- to 11-year-old children with hyper-
insulinemia. We calculated that among severely obese children, a total sample
size of 60 participants would detect a between-group difference of 0.09 BMI SD
score units (approximately equivalent to a 2 kg/m
2 difference) with 80% power.
Participant accrual was set at 100 participants to allow as much as 40% loss to
follow-up (46). The reported primary data analyses were prespeciﬁed and
analyzed using SPSS for Windows, version 14.0 (SPSS, Chicago, IL). Interim
analyses for efﬁcacy were performed by the Data Safety Monitoring Board
when 40 and 70 subjects had been enrolled for 6 months of randomized phase
treatment. Using the Lan-DeMets implementation of the O’Brien-Fleming
method, the critical two-tailed a values were deﬁned for each look, such that
a P value of 0.04515 was considered signiﬁcant at the end of the study. We
assessed efﬁcacy in the intention-to-treat sample of all randomly assigned
participants using a multiple imputation model for missing data under
a missing-at-random assumption. By using NORM, version 2.03 (Pennsylvania
State University, State University Park, PA), we included all available baseline
and follow-up measures in an imputation model. The imputation datasets were
obtained using a sequential chain of 1,200 iterations using initial parameter
estimates supplied by running the expectation-maximization (EM) algorithm.
Starting after the ﬁrst 200 iterations, data were sampled with 50 iterations
between successive imputations. Each of the imputation-completed datasets
was then analyzed separately using the prespeciﬁed ANCOVA model with
SPSS for Windows, version 14.0. BMI Z change (or change in each secondary
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independent variable; and age, sex, and race/ethnicity were covariates. We
then combined the coefﬁcients from analyses of the 20 imputed datasets
into a single set of estimates according to Rubin’s rules for scalar estimands.
To assess sensitivity of the results to the missing-at-random assumption, we
conducted three additional analyses: assuming that all participants who
withdrew from the study had major weight gain ($2.27 kg [$5 lb]); that those
who received metformin had no weight gain, whereas those who received
placebo had major weight gain; and that those who received placebo had no
weight gain, whereas those who received metformin had major weight gain.
We used multiple imputations to impute the missing 6-month weight mea-
surements by using the same imputation model used for the main analysis. For
the three scenarios, we added ﬁxed amounts to the imputed values, reanalyzed
the results by using ANCOVA, and combined them by using the Rubin rules
for scalar estimands. An additional conﬁrmatory analysis used the last-
observation-carried-forward method for individuals who did not complete
the study. Unadjusted analyses were also run both for the imputation and the
last-observation-carried-forward models. Because all of these models yielded
similar results, only the primary efﬁcacy model is presented. We examined
baseline characteristics by simple t tests or, in the case of categorical data,
with exact tests. Reports of adverse events were also examined by exact tests.
Funding and role of the sponsor. The intramural research programs of
NICHD and National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), NIH, and the National Center on Minority Health and Health Dis-
parities (NCMHD), NIH, which funded the study, had no role in study design,
data accrual, data analysis, or manuscript preparation. The authors designed
the study, wrote and made the decision to submit the manuscript for publi-
cation, and afﬁrmed the completeness, accuracy, and integrity of the data and
data analyses. Monitoring of the study, measurement and adjudication of study
end points, and statistical analyses were performed by the authors without
sponsor involvement. The manuscript was drafted by the principal investigator
and revised by the coauthors.
RESULTS
A total of 100 children were randomly assigned to the
two study groups (Fig. 1). There were no signiﬁcant
TABLE 1
Baseline participant characteristics
Metformin Placebo
N 53 47
Age (years) 10.1 6 1.6 10.4 6 1.4
Female sex (%) 57 64
Race/ethnicity (%)
Non-Hispanic white 42 49
Non-Hispanic black 42 38
Hispanic white 11 11
Other (Native American, Asian, or Paciﬁc Islander) 5 2
Family history of type 2 diabetes (%) 81 72
Parent with type 2 diabetes (%) 34 28
Pubertal status
Percentage prepubertal (%) 35.8 34.0
Boys’ testis volume (cc) 3.9 6 1.9 4.2 6 1.5
Girls’ breast stage [median (range)] II (I–III) II (I–III)
Skeletal age (years)* 11.6 6 1.9 11.9 6 1.4
Weight (kg) 76.4 6 23.1 80.1 6 20.5
BMI (kg/m2) 34.2 6 6.8 34.6 6 6.2
BMI range (kg/m2) 23.0–55.0 24.7–57.5
BMI SD score for age and sex 2.56 6 0.27 2.58 6 0.24
Fat mass by DEXA (kg)‡ 33.9 6 11.8 35.2 6 10.0
Fat mass by air displacement plethysmography (kg) 39.0 6 16.9 39.1 6 14.2
Waist circumference (cm) 105.4 6 15.1 106.1 6 14.2
Presence of acanthosis nigricans (%) 64 68
Systolic blood pressure (mmHg) 115.5 6 15.1 116.8 6 1.5
SD score for age, sex, and height 0.76 6 2.03 1.02 6 1.28
Diastolic blood pressure (mmHg) 65.6 6 9.8 64.3 6 10.2
SD score for age, sex, and height 0.17 6 1.17 0.13 6 0.92
Fasting plasma glucose (mg/dL) 92 6 89 2 6 8
Fasting serum insulin (mIU/mL) 19.8 6 8.9 21.7 6 13.5
HOMA-IR index† 4.5 6 2.2 4.9 6 3.3
Insulin sensitivity (from hyperglycemic clamp) (mg/kg/min per mIU/mL) 4.9 6 3.2 4.4 6 2.4
Serum triglycerides (mg/dL) 97.2 6 44.6 93.5 6 42.8
Total cholesterol (mg/dL) 162.8 6 30.1 151.1 6 34.9
LDL/HDL cholesterol ratio 2.92 6 0.96 2.78 6 0.75
HDL cholesterol (mg/dL) 40.2 6 9.0 40.2 6 7.8
LDL/HDL cholesterol ratio 2.92 6 0.96 2.78 6 0.75
Diagnosis of pediatric metabolic syndrome (%)§ 26.4 31.9
AST (U/L) 23.8 6 8.3 26.0 6 12.5
ALT (U/L) 24.8 6 5.5 24.7 6 6.3
High-sensitivity C-reactive protein (mg/dL) 0.56 6 0.43 0.74 6 1.03
Serum vitamin B12 (pg/mL) 683 6 270 694 6 265
Data are means 6 SD unless otherwise indicated. At baseline, there were no signiﬁcant differences between treatment groups (all P . 0.32).
Race and ethnicity were self-reported. *Skeletal age according to Greulich and Pyle method. †HOMA-estimated insulin resistance. ‡Two
subjects, one from each group, weighed .136 kg and could not be scanned using DEXA. §Diagnosis of pediatric metabolic syndrome was
made when three or more components were present from among the following: waist circumference, blood pressure, and triglycerides $90th
percentile for age and sex, HDL cholesterol #10th percentile for age and sex, and fasting glucose $100 mg/dL (44).
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pated and subjects who declined. Participants had evi-
dence of signiﬁcant insulin resistance; a family history of
type 2 diabetes was also frequently reported (Table 1).
When separated into prepubertal subjects and subjects
who had evidence for pubertal onset (i.e., in boys, testes
.3 mL; in girls Tanner II or greater breast stage), there
were no signiﬁcant differences between groups in de-
mographic, historical, or laboratory data (all P . 0.46),
including degree of insulin resistance (HOMA-IR metfor-
min prepubertal: 4.3 6 2.0, pubertal: 4.6 6 2.3; placebo
prepubertal: 4.5 6 4.1, pubertal: 5.0 6 2.9).
Of the participants, 85% completed the 6-month ran-
domized trial (85% metformin; 85% placebo, P=0.98).
Among the 85 offered open-label metformin, 67% completed
the second 6-month study phase (Fig. 1). Sociodemographic
and baseline anthropometric or laboratory indexes did not
signiﬁcantly differ between participants who did and did not
complete either phase of the study (all P . 0.65).
Changes in body weight and body composition. During
the placebo-controlled randomized phase (Table 2 and
Fig. 2), both metformin-treated and placebo-treated chil-
dren signiﬁcantly reduced BMI Z (P values ,0.01); how-
ever, children given metformin had signiﬁcantly greater
decreases in BMI Z (difference between metformin and
placebo groups 20.07, 95th CI 20.12 to 20.01, P = 0.02),
BMI (difference 21.09 kg/m
2,C I21.87 to 20.31, P =
0.006), body weight (difference 23.38 kg, CI 25.2 to
21.57, P , 0.001), and total-body fat mass (P , 0.05).
Three metformin-treated versus 0 placebo-treated children
lost sufﬁcient weight to reach a BMI ,97th percentile
after 6 month of treatment (P = 0.25). Body circum-
ference and skinfold thickness measurements decreased
to a signiﬁcantly greater extent in the metformin-treated
children, although changes in intra-abdominal fat did not
differ signiﬁcantly between groups (Table 2). During the
open-label phase, subjects who previously received pla-
cebo signiﬁcantly decreased BMI Z; subjects treated con-
tinuously with metformin had nonsigniﬁcant increases in
BMI Z (Fig. 2) compared with their 6-month values and
increases in absolute BMI consistent with those expected
to occur as children mature. Subjects examined at the end
of the open-label phase had signiﬁcantly lower BMI Z at
the end of the 12-month treatment period when compared
with their BMI Z values at baseline (20.091, CI 20.183 to
20.001, P = 0.05). Additional analyses that included an
interaction term for race 3 treatment group found non-
Hispanic black participants decreased body mass less than
non-Hispanic or Hispanic whites during the randomized
treatment phase (BMI Z 20.035 6 0.021 vs. 20.108 6
0.017, difference 0.073, CI 0.020–0.127, P = 0.008), but the
interaction between race and treatment group was not
FIG. 1. Flow of participants throughout the trial.
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resistance or pubertal status at baseline was included in
the statistical model for the primary or secondary body
composition outcomes, no signiﬁcant impact for severity
of insulin resistance or puberty on treatment success was
identiﬁed, even after race was removed from the analysis
(all P $ 0.20).
Changes in insulin resistance and metabolic
consequences of obesity. Fasting serum insulin (P =
0.02), plasma glucose (P = 0.02), and HOMA-IR index
TABLE 2
Changes in anthropometric variables at conclusion of the randomized phase
Characteristic Metformin Placebo Difference P
N 53 47
BMI SD score 20.11 (20.16 to 20.05) 20.04 (20.1 to 0.02) 20.07 (20.12 to 20.01) 0.02
BMI (kg/m
2) 20.78 (21.54 to 20.01) 0.32 (20.54 to 1.18) 21.09 (21.87 to 20.31) 0.006
Weight (kg) 1.47 (20.31 to 3.24) 4.85 (2.84 to 6.85) 23.38 (25.2 to 21.57) ,0.001
Fat mass by DEXA (kg) 0.48 (20.80 to 1.76) 1.88 (0.44 to 3.31) 21.40 (22.74 to 20.06) 0.04
Fat mass by air displacement
plethysmography (kg) 21.51 (24.56 to 1.54) 1.81 (21.64 to 5.25 23.32 (26.49 to 20.14) 0.04
Abdominal circumference (cm) 1.84 (21 to 4.69) 4.38 (1.23 to 7.53) 22.54 (24.57 to 20.5) 0.02
Hip circumference (cm) 20.44 (22.76 to 1.87) 1.84 (20.72 to 4.41) 22.29 (23.97 to 20.6) 0.009
Triceps skinfold thickness (mm) 22.64 (26.79 to 1.5) 1.65 (22.94 to 6.24) 24.29 (27.28 to 21.3) 0.006
Abdominal adipose tissue (cc)
L2–3 subcutaneous 7.4 (225.7 to 40.5) 22.7 (213.7 to 59.1) 215.3 (237.6 to 7.1) 0.18
L4–5 subcutaneous 221.6 (255 to 11.7) 1.0 (235.6 to 37.7) 222.7 (245.1 to 20.2) 0.05
L2–3 intra-abdominal 2.5 (226.1 to 31.0) 8.5 (223.0 to 40.0) 25.9 (225.3 to 13.4) 0.54
L4–5 intra-abdominal 2.1 (219.7 to 23.8) 4.4 (219.5 to 28.3) 22.3 (217 to 2.4) 0.76
Systolic blood pressure SD score 0.20 (20.88 to 1.28) 20.17 (21.38 to 1.05) 0.37 (20.54 to 1.28) 0.42
Diastolic blood pressure SD score 20.02 (20.67 to 0.62) 20.19 (20.91 to 0.54) 0.16 (20.38 to 0.7) 0.56
Estimated marginal means (95% CIs), adjusted for covariates, were reported from multiple imputation analyses.
FIG. 2. Changes in BMI during the study. Mean 6 SEM for BMI SD score (BMI Z) and BMI during the randomized placebo-controlled phase (A and
C) and the open-label phase when all participants were offered metformin (B and D). A: BMI Z score, randomized phase. B: BMI Z score, open-label
phase. C: BMI, randomized phase. D: BMI, open-label phase. Intent-to-treat imputed data analyses are shown. There were signiﬁcant group by time
interactions (P < 0.001) during each phase for both BMI Z and BMI. *P < 0.05; **P < 0.01 for comparison of children randomized to metformin and
placebo at each time point.
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in placebo-treated children (Table 3). However, neither
ﬁrst-phase insulin secretion (P = 0.34) nor insulin sensi-
tivity (P = 0.52) estimated from the hyperglycemic clamp
study differed signiﬁcantly between groups. Changes in
other laboratory values commonly observed to improve
with signiﬁcant weight reduction did not differ signiﬁ-
cantly between the groups (Table 3). The prevalence of
metabolic syndrome was not altered signiﬁcantly by met-
formin treatment (P = 0.71).
Adverse events and adherence. No serious or life-
threatening adverse events were reported. No subject de-
veloped abnormal AST or ALT concentrations or acidosis.
Serum vitamin B12 remained within the normal range (220–
960 pg/mL) in all subjects throughout the 12-month study,
but decreased in the metformin-treated group, compared
with the increase observed in placebo-treated children
during the randomized phase (257 6 58 vs. 173 6 67 pg/mL,
P , 0.001). No metformin-associated difference in hemo-
globin concentrations was observed (P = 0.53). Gastroin-
testinal complaints were signiﬁcantly more prevalent
among subjects treated with metformin. More metformin-
than placebo-treated subjects reported at least one epi-
sode of liquid or loose stools (41.5%, CI 30.1–55.9% vs. 17%,
CI 7.6–30.8%, P = 0.01) and vomiting (41.5%, CI 29.1–55.9%
vs. 21.3%, CI 10.7–32.7%, P = 0.05). Fatigue was also sig-
niﬁcantly more likely to be reported (P = 0.02) among
metformin-treated (37.7%, CI 24.8–52.1%) than placebo-
treated (14.9%, CI 6.2–28.3%) children. One metformin-
treated child lost interest in usual pleasurable activities
that resolved with medication discontinuation, but this
adverse event did not recur during a rechallenge. Reported
metformin-associated symptomatology was most prevalent
in the ﬁrst month of treatment and then decreased such that
no reported symptom was signiﬁcantly different in preva-
lence between the two groups at the end of the placebo-
controlled phase (Fig. 3) or during the open-label phase.
A total of nine metformin-treated children (17.0 vs. 2.1%
placebo-treated, P = 0.03) were unable to take the highest
dose (2,000 mg/day) and were prescribed doses ranging
from 500 to 1,500 mg/day at conclusion of the randomized
phase; however, only one subject discontinued the trial
because of medication intolerance. Children for whom the
full metformin dose could not be prescribed were younger
(8.8 6 1.9 vs. 10.3 6 1.4 years, P = 0.01) but did not differ
in BMI or fat mass from those who tolerated it. Adherence
to the prescribed study medication regimen did not differ
signiﬁcantly among the groups during the randomized
phase (93.2 6 1.3 vs. 92.2 6 2.3%).
DISCUSSION
Childhood-onset obesity presages the development of
disorders that predispose to cardiovascular disease in later
life (47,48). Prevention of the complications of obesity,
including type 2 diabetes, thus is a primary medical goal
for weight-reduction therapy in children. On the basis of
evidence suggesting that adolescents given metformin
have salutary changes in adiposity and obesity-related
comorbid conditions (27–33) and data from adults sug-
gesting that metformin can delay the incidence of type 2
diabetes (22,23), we tested the hypothesis that metformin
could improve glucose homeostasis and decrease the
weight and body fat gained by obese insulin-resistant 6- to
12-year-old children who participated in a low-intensity
clinic-based weight-reduction program.
Metformin produced modest differences in BMI Z that,
as found for adolescents (33), largely persisted during
1 year of treatment. Compared with placebo treatment,
metformin improved several other measures of body fat-
ness, although consistent with some (33) but not all (29,39)
studies, metformin did not signiﬁcantly change intra-
abdominal adipose tissue. As might be anticipated because
of its major effect to suppress hepatic gluconeogenesis
(14), metformin improved fasting insulin, glucose, and the
HOMA-IR index, measures of insulin sensitivity that ap-
pear principally to reﬂect hepatic sensitivity to insulin’s
actions (49), but metformin did not greatly alter whole-
body (primarily muscle) insulin sensitivity. Among young
adult Israeli army recruits, individuals with fasting glucose
concentrations .86 mg/dL had monotonically increasing
risks for developing diabetes during ;6 years of follow-up
TABLE 3
Changes in laboratory variables at conclusion of the randomized phase
Metformin Placebo Difference P
N 53 47
Serum insulin (mIU/mL) 3.24 (21.36 to 7.84) 9.0 (3.84 to 14.15) 25.75 (210.45 to 21.06) 0.02
Plasma glucose (mg/dL) 20.88 (23.81 to 2.05) 3.47 (0.13 to 6.82) 24.35 (27.51 to 21.19) 0.007
HOMA-IR index* 0.68 (20.4 to 1.76) 2.23 (1.02 to 3.43) 21.54 (22.65 to 20.44) 0.006
First-phase insulin secretion (mIU/mL) 27.26 (231.4 to 16.88) 224.7 (252.8 to 3.4) 17.44 (218.61 to 53.49) 0.34
Clamp insulin sensitivity
(mg/kg $ min/mU/mL) 0.53 (20.77 to 1.83) 20.19 (21.64 to 1.27) 0.71 (21.56 to 2.99) 0.52
Total cholesterol (mg/dL) 29.05 (216.64 to 21.47) 24.52 (213.03 to 4.00) 24.54 (212.53 to 3.46) 0.27
HDL cholesterol (mg/dL) 0.12 (22.55 to 2.78) 20.27 (23.28 to 2.73) 0.39 (22.49 to 3.28) 0.79
LDL cholesterol (mg/dL) 26.57 (214.09 to 0.95) 22.78 (211.34 to 5.78) 23.79 (212.02 to 4.43) 0.37
LDL/HDL cholesterol ratio 20.15 (20.43 to 0.12) 20.003 (20.27 to 0.27) 20.12 (20.40 to 0.15) 0.21
Triglycerides (mg/dL) 7.7 (212.83 to 28.23) 3.79 (219.39 to 26.96) 3.91 (217.67 to 25.5) 0.72
AST (U/L) 20.86 (23.04 to 1.31) 20.89 (23.36 to 1.57) 0.03 (22.27 to 2.33) 0.98
ALT (U/L) 3.01 (20.71 to 6.73) 2.63 (21.65 to 6.92) 0.38 (23.72 to 4.48) 0.86
High-sensitivity C-reactive protein
(mg/dL) 0.07 (20.48 to 0.61) 0.33 (20.33 to 0.98) 20.26 (20.95 to 0.43) 0.45
Vitamin B12 (pg/mL) 257.1 (2170.3 to 56.1) 173.8 (42.6 to 305.1) 2230.9 (2356.9 to 2105.0) ,0.001
Estimated marginal means (95% CIs), adjusted for covariates including age, race, and sex, were reported from multiple imputation analyses.
*HOMA-estimated insulin resistance.
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92 mg/dL, decreasing slightly among metformin-treated
children but increasing an additional 3.5 mg/dL in the
placebo-treated group. The ﬁnding that metformin enabled
study subjects to maintain fasting plasma glucose at a
lower level suggests the possibility that metformin treat-
ment might prevent or delay the onset of type 2 diabetes in
children at high risk for this disorder. Other aspects of the
insulin resistance–related metabolic syndrome did not
change signiﬁcantly with metformin treatment. The limited
weight change observed, perhaps combined with the wors-
ening of whole-body insulin resistance that commonly
occurs as children enter adolescence, may account for
the failure to ﬁnd greater improvements in metabolism as
a result of metformin treatment in this and prior studies
conducted among adolescents (33,35).
Metformin therapy was associated with dose-limiting
side effects in almost 17% of participants, particularly
among younger subjects. Inability to tolerate 2,000 mg/day
despite efforts made to reach the full dose may have lim-
ited the efﬁcacy that could be observed. To some extent,
the variability in the dose administered makes determi-
nation of metformin’se f ﬁcacy more difﬁcult. Our data
suggest that a target total daily dose of 2,000 mg/day may
not be achievable for all young children treated with
metformin. Other studies report good toleration of lower
doses (39) but a similar side effect proﬁle among adoles-
cents treated with 2,000 mg/day extended-release metfor-
min (33). In addition to nausea and loose stools, we also
observed fatigue symptomatology previously reported
among children given metformin. Lastly, there was a relative
diminution of serum vitamin B12 despite provision of a
cyanocobalamin-containing multivitamin. B12 deﬁciency is
unlikely to be reported among children treated with met-
formin because a long period of inadequate dietary B12
intake is required before clinical deﬁciency becomes man-
ifest, but metformin has been reported to diminish serum
B12 by 14–30% in adults, with the greatest effects observed
among individuals treated with metformin for the longest
time at the highest dosage (51). Our data reinforce the
importance of monitoring potential adverse events among
patients treated chronically with metformin.
Although this study is among the largest randomized
controlled trials to date of a pharmacotherapeutic agent
conducted for amelioration of obesity among young chil-
dren, a limitation of this study is that only 100 children
were studied; thus, there may have been insufﬁcient power
to detect differences between placebo- and metformin-
treated groups for some obesity-related comorbid con-
ditions examined. The placebo-controlled interval was
only 6 months in duration and the maximal treatment du-
ration was 1 year; thus, the study did not explore the ef-
ﬁcacy of metformin in the longer term, which is required
for a chronic condition like obesity. The study’s general-
izability is also somewhat limited by the fact that only
severely obese insulin-resistant children were enrolled;
it remains unclear how efﬁcacious metformin is among
children who are less obese and insulin resistant. Wilson
et al. (33) have found quite similar results among ado-
lescents who were not required to have insulin resistance.
Finally, because the weight loss intervention was intended
to model to some extent what might be available in clinical
FIG. 3. Reports of symptoms during the placebo-controlled phase. *P < 0.05; **P < 0.01 for comparison of children randomized to metformin and
placebo at each time point. A: Nausea. B: Vomiting. C: Loose or liquid stools. D: Fatigue.
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etitian, and the magnitude of metformin-associated weight
reduction that might occur among children treated with an
intensiﬁed behavioral modiﬁcation regimen is not estab-
lished. Strengths include the recruitment of children who
were racially and ethnically diverse, the use of intensive
assessments of body composition and insulin sensitivity,
the careful determination of adverse events using struc-
tured reporting tools, and the excellent subject retention
rate.
We conclude that metformin treatment modestly re-
duces body weight and adiposity and improves measures
of glucose homeostasis in obese insulin-resistant 6- to
12-year-old children. Although the weight loss produced is
small, metformin treatment may hold promise as a method
to prevent or delay the appearance of impaired glucose
homeostasis in children at high risk for the development of
type 2 diabetes.
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